PubMed Health⌕ Search

Biomedical subjects

H Garwolińska

Publications and source records attributed to H Garwolińska.

At least 19 recordsLinked to original sources
PubMed1992

[A comparative evaluation of combined immunocorrective therapy in rheumatoid arthritis with systemic manifestations (joint Soviet-Polish research)].

Thirty-two patients with rheumatoid arthritis were included in the trial. Each of them was assigned to one of the 4 groups comparable by the main features. Each group entered 8 patients. Group 1 patients underwent hemosorption weekly for 3 weeks. After the second procedure cyclophosphamide was added at a single IV dose 1000 mg. After the third procedure the treatment was continued with methotrexate (7.5 mg, weekly). Group 2 began the treatment with methotrexate (7.5 mg, weekly). Group 3 received cyclophosphamide 200 mg IV twice a week 6 times and then 200 mg weekly orally till a total dose of 2 g. Group 4 received azathioprine in a daily dose 100 mg. The treatment with nonsteroidal antirheumatic drugs and corticosteroids was continued unchanged. After 6 months we did not see significant differences between the 4 groups.

Adult↗
PubMed1986

A trial of cyclophosphamide in ankylosing spondylitis with involvement of peripheral joints and high disease activity.

In 12 patients with ankylosing spondylitis with involvement of the peripheral joints and high activity of the disease process, cyclophosphamide was given in intravenous doses of 200 mg every second day for 3 weeks, followed by oral doses of 100 mg once weekly for 3 months to a total dose of 3 300 mg. Before this treatment and after 18-24 months the following clinical parameters were determined: spinal mobility, degree of intensity of spinal and articular pains, and the number of involved joints. After the treatment an evident clinical improvement was observed, with decreased values of the laboratory indices of the disease activity. Apart moderate erythrocyturia in one case and transient leukopenia in another case, no other side effects were observed. The improvement in cases with coexistent amyloidosis was relatively small.

Adult↗
PubMed1984

Latent collagenase of rheumatoid synovial fluid is not of granulocytic origin.

The physicochemical properties of three latent collagenases derived from rheumatoid synovial fluid, polymorphonuclear leucocytes and culture medium of rheumatoid synovium were compared. It has been shown that synovial fluid enzyme is similar to that of synovium collagenase from tissue culture and differs significantly in molecular size and protein charge from granulocyte collagenase. The results indicate that the latent, trypsin-activable collagenase present in rheumatoid synovial fluid is not of granulocytic origin and seems to derive from the synovial membrane.

Arthritis, Rheumatoid↗